Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn’s Disease: Analyses of Phase I and II Trials

BACKGROUND AND OBJECTIVES: Risankizumab is a humanized anti-interleukin-23 monoclonal antibody in development for the treatment of several inflammatory diseases. This work characterized the pharmacokinetics of risankizumab and evaluated covariates that may affect its exposures using phase I and II t...

Descripción completa

Detalles Bibliográficos
Autores principales: Suleiman, Ahmed A., Khatri, Amit, Minocha, Mukul, Othman, Ahmed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373392/
https://www.ncbi.nlm.nih.gov/pubmed/30123942
http://dx.doi.org/10.1007/s40262-018-0704-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373392/
https://www.ncbi.nlm.nih.gov/pubmed/30123942
http://dx.doi.org/10.1007/s40262-018-0704-z

Ejemplares similares